Needham & Company LLC Reiterates Buy Rating for Artivion (NYSE:AORT)

Artivion (NYSE:AORTGet Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. They currently have a $34.00 price objective on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 8.80% from the company’s previous close.

A number of other brokerages have also recently weighed in on AORT. Oppenheimer lifted their price target on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. JMP Securities reissued a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research note on Tuesday, December 10th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $31.80.

View Our Latest Research Report on AORT

Artivion Stock Performance

Shares of NYSE:AORT opened at $31.25 on Tuesday. The firm’s 50 day simple moving average is $29.40 and its 200 day simple moving average is $27.41. Artivion has a fifty-two week low of $16.48 and a fifty-two week high of $32.33. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -1,562.55 and a beta of 1.74. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Insider Activity at Artivion

In other news, CAO Amy Horton sold 4,329 shares of the firm’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the transaction, the chief accounting officer now directly owns 135,660 shares of the company’s stock, valued at $4,023,675.60. This trade represents a 3.09 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jean F. Holloway sold 8,070 shares of Artivion stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total transaction of $243,068.40. Following the completion of the sale, the senior vice president now owns 153,862 shares in the company, valued at $4,634,323.44. This trade represents a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 20,017 shares of company stock valued at $600,007. 8.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its position in Artivion by 2.9% during the 3rd quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company’s stock worth $44,090,000 after buying an additional 46,267 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Artivion by 58.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock valued at $9,074,000 after acquiring an additional 125,668 shares during the last quarter. Lord Abbett & CO. LLC acquired a new position in Artivion during the third quarter valued at approximately $5,798,000. Tidal Investments LLC boosted its position in Artivion by 602.2% during the third quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock valued at $4,179,000 after purchasing an additional 134,642 shares during the last quarter. Finally, Sio Capital Management LLC bought a new position in Artivion in the third quarter valued at approximately $3,226,000. Institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

(Get Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Further Reading

Analyst Recommendations for Artivion (NYSE:AORT)

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.